EDUCATING LEADERS IN PHARMACY AND PHARMACEUTICAL SCIENCES SINCE 1886
Join faculty, post-doctoral fellows and graduate students from the School of Pharmacy and Pharmaceutical Sciences for the 18th Annual Center for Protein Therapeutics (CPT) Symposium. The symposium presents the results of the research projects funded by the CPT during the past year.
The Symposium will be held in a hybrid format, both in-person and via Zoom. There is no fee for the Symposium for members of CPT Consortium Sponsors or for students, fellows, or faculty of the University at Buffalo.
Registration information coming soon
| Time | Presentation | Presenter/Lab |
|---|---|---|
| 8:50 a.m. | Introduction to the Annual CPT Symposium | Joseph Balthasar, PhD |
| 9:00 a.m. | Quantitative Investigation of Target-Mediated Drug Disposition via Fluorescence-Based Internalization and QSPKR Modeling | Mager Lab |
| 9:30 a.m. | Informing PBPK models for bispecific constructs through investigation of relationships between single-cell RNA sequence data and cell-surface protein expression | Balthasar Lab |
| 10:00 a.m. | Critical Investigation of the Differential Pharmacology of Dual-Payload ADC | Shah Lab |
| 10:30 a.m. | Break | |
| 11:00 a.m. | Comparative evaluation of anti-idiotypic distribution enhancers and priming doses of naked mAb for enhancing ADC efficacy in small and large tumors | Balthasar Lab |
| 11:20 a.m. | Biodistribution and kinetics of membrane permeable ADC payloads and ADC in extra-cellular space, cell membrane, cytosol and microtubule compartments | Qu Lab |
| 11:40 a.m. | Continuous time tracking of immune activation, exhaustion, and therapeutic perturbation in the tumor microenvironment | Talkington Lab |
| 12:00 p.m. | Break | |
| 1:00 p.m. | Development and Validation of IVIVC and PBPK/PD of siRNA Therapeutics | Woo Lab |
| 1:20 p.m. | Development of Translational PBPK Model to Characterize Brain Disposition of Antibody-Conjugated and Non-Conjugated Oligonucleotides (FDCs) | Shah Lab |
| 1:40 p.m. | Evaluation of Strategies to Overcome the Binding-Site Barrier for ADCs | Shah Lab |
| 2:00 p.m. | In Vitro Evaluation of the Improved Therapeutic Index of Bi-specific ADC | Shah Lab |
| 2:20 p.m. | Systematic Analysis of RNA-seq and Proteomic Data | Mager Lab |
| 2:40 p.m. | Break | |
| 3:10 p.m. | Investigation of the Determinants for Therapeutic Antibody Biodistribution to the Placenta and Embryo at Different Stages of Development | Shah Lab |
| 3:30 p.m. | Prediction of immunogenicity and its consequence: Integration of Preclinical Data, PK/PD Information, and a LLM to inform on biologics drug design and modelling | Balu-Iyer Lab |
| 3:50 p.m. | PBPK Model to Characterize Maternal to Fetal Transfer of Antibody-Based Therapeutics | Shah Lab |
| 4:10 p.m. | Systems Pharmacology Modeling of Chimeric Antigen Receptor (CAR) T-cell Induced Neurotoxicity | Mager Lab |
| 4:30 p.m. | Assessment of factors that mediate TROP2-targeting antibody drug conjugate intracellular localization and changes associated with drug resistance | Sprowl Lab |
| 4:50 p.m. | Translational PBPK Model for Protein Tx with Different Size and FcRn Affinity | Shah Lab |
| 5:10 p.m. | Concluding Remarks | Joseph Balthasar, PhD |